Univariate analyses of clinical factors for PFS and OS
| PFS | OS | |||
| HR (95% CI) | Log-rank p value | HR (95% CI) | Log-rank p value | |
|
ECOG PS
0–1 vs 2 | 0.70 (0.47 to 1.06) | 0.09 | 0.42 (0.26 to 0.68) | <0.001 |
|
Age
(<70 vs ≥70) | 1.07 (0.78 to 1.49) | 0.67 | 0.74 (0.50 to 1.12) | 0.15 |
|
Sex
Female vs male | 1.16 (0.84 to 1.61) | 0.36 | 1.20 (0.80 to 1.80) | 0.39 |
|
Smoking status
Current/ever vs never | 0.62 (0.36 to 1.07) | 0.08 | 0.87 (0.44 to 1.73) | 0.70 |
|
Histology
Non-squamous vs squamous | 0.78 (0.50 to 1.22) | 0.27 | 0.86 (0.49 to 1.49) | 0.59 |
|
KRAS mutation
No vs yes | 0.85 (0.61 to 1.20) | 0.36 | 0.78 (0.51 to 1.19) | 0.25 |
|
Brain metastases
Present vs absent | 1.28 (0.90 to 1.83) | 0.17 | 1.24 (0.80 to 1.92) | 0.34 |
|
PD-L1 expression
90%–100% vs 50%–89% | 0.65 (0.47 to 0.90) | 0.01 | 0.58 (0.38 to 0.87) | 0.01 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival .